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Background: Hereditary Tyrosinemia type I (HTI) is a metabolic disease caused by deficiency of fumarylacetoacetate hydrolase enzyme.
Objectives: This study reports beside its clinical and biochemical presentation, the outcome of NTBC [2- (2-nitro-4-trifloro-methylbenzoyl)-1, 
3-cyclohexanedion] treatment of the disease and evaluates its biochemical markers in 16 pediatric Libyan patients.
Patients and Methods: The diagnosis was based on presence of high tyrosine levels in blood and succinylacetone in urine.
Results: The consanguinity rate was 81.2%, the median age at onset, at diagnosis and at starting treatment were 4.5, 8, and 9.5 months 
respectively. At presentation hepatomegaly, jaundice, rickets and high gamma glutamyl transferase (GGT) were observed in 87.5% of 
patients. All patients had extremely high alpha fetoprotein (AFP) and high alkaline phosphatase (ALP) levels. Fifteen patients were treated 
with NTBC, normalization of PT (Prothrombine time) was achieved in average in 14 days. The other biochemical parameters of liver 
function (transaminases, GGT, ALP, bilirubin and albumin) took longer to improve and several months to be normalized. Survival rate 
with NTBC was 86.6%. Patients who started treatment in a median of 3 months post onset observed a fast drop of AFP in 90.6% of patients 
(P = 0.003). Abnormal liver function and rickets were the common presentations, GGT was an early cholestatic sensitive test. ALP was 
constantly high even in asymptomatic patients.
Conclusions: In HT1 a faster dropping of AFP is a marker of good prognosis.
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1. Background
Hereditary Tyrosinemia type I (HTI) is an autosomal 
recessive metabolic disorder due to deficiency of fu-
marylacetoacetate hydrolase enzyme. The diagnosis 
is based on high blood tyrosine level and abnormal 
urinary excretion of succinylacetone (SA) (1). Accord-
ing to onset of symptoms HT1 is classified in acute (< 
2 months), subacute (2 to 6 months) and chronic (> 6 
months) forms (2). Most common causes of death are 
liver failure and bleeding, hepatocellular carcinoma 
(HCC) and pseudo porphyric crisis with respiratory 
failure (3). Since 1992, the 2- (2-nitro-4trifluoro-methyl 
benzoyl)-1, 3-cyclohexanedione (NTBC) has offered as a 
new promising tool for the treatment (4, 5). This treat-
ment prevents production of toxic and carcinogenic 
metabolites (6). Yet, there are few reports of the long-
term prognosis (5, 7).
2. Objectives
This study reports beside its clinical and biochemical 
presentation, the outcome of NTBC [2- (2-nitro-4-trifloro-
methylbenzoyl)-1, 3-cyclohexanedion] treatment of the 
disease and evaluates its biochemical markers in 16 pedi-
atric Libyan patients.
3. Patients and Methods
A retrospective clinical study was undertaken on 16 
Libyan patients with hereditary tyrosinemia type I 
(HTI) who were diagnosed or referred to a single cen-
ter at Elkhadra hospital, one of the main referral hospi-
tals in western Libya, which provides medical services 
to pediatric age groups up to 16 years old. These pa-
tients were followed during the period from October 
2001 to October 2010. Our orientation was based on 
the presence of rickets with hepatomegaly or liver dis-
ease with high alpha fetoprotein (AFP). Two patients 
were detected by screening at the age of one week and 
1.5 months because of older affected siblings. The di-
agnosis of HTI was confirmed by high tyrosine level 
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in blood and SA urinary excretion by liquid chroma-
tography tandem mass spectrometry (LC-MS/MS). The 
investigation (blood for amino acids, urine for organic 
acids and SA or dried blood spots for the same tests) 
were sent to laboratories and were done either in Tu-
nisia, Germany, France or Lebanon. X-ray of bones, 
echocardiography, abdominal ultrasonography and 
when indicated, abdominal CT scan were monitored. 
Follow up visits were done iat least monthly in the first 
6 months, then every 3 months thereafter. Serum tyro-
sine was regularly monitored. AFP and liver imaging 
were used as tumor markers. One patient was treated 
with diet protein restriction due to unavailability of 
NTBC on diagnosis; and 15 patients were treated with 
NTBC (initially 1 mg/kg/day in 2 divided doses, the 
dose thereafter was adjusted according to clinical re-
sponse ranging 0.5 - 2 mg/kg/day) (8, 9). Prescribed 
diet consisted of avoiding high protein, continuing 
breast feeding and employing a special milk formula. 
The goal of the diet was to maintain the blood levels 
of tyrosine below 500 µmol/L (by restricted tyrosine 
and phenylalanine each one dose not exceed 200 mg/
day). Supplementation by fat soluble vitamins D and K 
in liver dysfunction and phosphate in hypophosphate-
mia were provided.
3.1. Statistical Analysis
With SPSS program version 16 the paired samples t-test was 
used, P value < 0.05 was considered statistically significant.
4. Results
Sixteen patients were diagnosed with HTI, rate of di-
agnosis was 1 - 2 children/year, 81.2% (n = 13) were born 
to consanguineously married couples, and 2 families 
had 2 affected children each. The median age at on-
set of first symptoms was 4.5 months (range 1 week 
- 8 months). Median age of first visit presentation to 
our unit was 7 months (range: 1 week to 38 months). 
The median age at diagnosis was 8 months (range 1 
week - 40 months). The median age at starting treat-
ment was 9 months (range 1 week - 43 months), the 
median interval between diagnosis and treatment 
was 0.5 months (range 0 - 11 months). The main clini-
cal presentation at first visit was hepatomegaly, jaun-
dice, rickets with prolonged PT and hypophosphate-
mia which were seen in 14 (87.5%) patients. Bleeding 
tendency, ascites and edema with abnormal nodular 
liver imaging were seen in 3 (18.7%) patients with liver 
failure. Low corrected calcium was seen in 50% (n = 8). 
Low albumin was observed in 5 patients with severe 
rickets. Anemia and thrombocytopenia (5 patients) 
were transient and normalized after initiation of 
treatment. Other associated less common presenta-
tions were night irritability (3 patients), severe failure 
to thrive (3 patients), multiple fractures (1 patient) 
(Figure 1). No child had symptoms related to cardio-
vascular or central nervous system (Tables 1 and 2). 
At presentation, extremely high AFP (Figure 2) and 
high ALP were seen in all patients, the GGT was high in 
87.5% (n = 14) but was normal for age in 2 patients who 
were diagnosed by screening, ALT was high in 68.7% (n 
= 11) and AST in 56.2% (n = 9) (Table 2). Overall 9-year 
survival rate has been 81.2% whereas it was 86.6% in 
NTBC treated patients.
We compared the onset of treatment and the drop of 
AFP levels in two groups. The first group was five pa-
tients with poor response who began treatment at me-
dian of 13 months post onset of first symptoms (range: 
sex to 35 months). The second group was 11 patients 
with good response who began treatment at median 
of three months post onset of first symptoms (range: 
one to 14 months). We observed that by the third month 
post treatment that level of AFP in the second group 
had faller by more than 50% of pre-treatment values in 
90% (n.10) of patients. We observed this drop in only 
20% (n.1) of the first group (P = 0.003).
The outcome of NTBC treatment after one year in 13 
survived patients was as follows: PT was the first liver 
function marker that showed normalization (median 
14 days, range 0 - 240 days), while other biochemical 
liver markers such as transaminases (GPT, GOT), GGT, 
ALP, bilirubin, serum albumin, AFP and renal func-
tion took longer to improve. In acute form all these 
were normal after one year of treatment. In subacute 
form, normalization of AFP was 50% in the first year 
and 100% in the second year, PT was normalized 100% 
and other liver markers 75%; one patient had ab-
normal liver imaging (hepatomegaly without nod-
ules which sustained for longer). In chronic form, 
normalization of AFP was 16.6% and 83.3% in the 3rd 
year and later, the PT was 83.3% and other liver func-
tion markers were normalized in 66.6%; persistence 
of abnormal liver imaging (hepatomegaly) was seen 
in one patient. In none of forms increase of AFP was 
seen (Figure 2). The constant features were decreased 
rates of weight gain and poor dentition, caries or 
delayed eruption of deciduous teeth occurred in all 
patients, the first permanent teeth erupted at due 
time and were healthy. Neuropsychosocial develop-
ment, motor function and speech were normal for 
age in all survived patients, but are not assessed by 
any standardized test system. Six patients in school 
age attended school without difficulties (10). Three 
patients who presented severe liver cirrhosis (sple-
nomagly, esophageal varices with PT 21% to 24%) 
and persisting high AFP died. They were at onset of 
symptoms 1, 5 and 8 months, and at diagnosis 6, 6, 40 
months old. The treatment was started at 7 months 
(diet only), 8 months and 43 months (NTBC and diet). 
They died at 9, 13, and 49 months, respectively.
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Figure 1. X-Ray of the Radius and Ulna Showing Hypophosphatemic Rick-
ets With Fracture
Table 1. Demographics of 16 Patients Diagnosed With HTI
Variables Values a
Consanguinity 13 (81.2)
Family history of undiagnosed similar illness 9 (56.2)
Origin
West Libya 10 (62.5)
East Libya 6 (37.5)
Gender
Male 8 (50.0)
Female 8 (50.0)
Age at onset, months
2 3 (18.7)
2 - 6 5 (31.2)
6 8 (50.0)
Patients treated with NTBC 15 (93.7)
Died (2 with NTBC, 1 diet only) 3 (18.7)
Age at onset of 1st symptom, mo (wk - mo) 4.5 (1 - 8)
Age at presentation to the unit, mo (wk - mo) 7 (1 - 38)
Age at diagnosis, mo (wk - mo) 8 (1 - 40)
Age at start of treatment (16 patients), mo (wk 
- mo) 9.5 (1 - 43)
Age at start of NTBC (15 patients), mo (wk - mo) 9 (1 - 43)
Interval between 1st symptom and diagnosis, 
mo (wk - mo) 3 (0 - 32)
Duration between diagnosis and treatment, 
mo (wk - mo) 0.5 (0 - 11)
Clinical presentation
Hepatomegaly and jaundice 14 (87.5)
Bleeding tendency (melena, epistaxis, hema-
tamesis)
3 (18.7)
Ascites, edema, nodular liver 3 (18.7)
Rickets 14 (87.5)
a  Values are presented as No. (%).
Table 2. Laboratory Results of 16 Patients at Presentation a
Variable Median (Range) No. (%)
High alpha fetoprotein ( N. ˂ 10 µg/L) 62014 (722 - 97425) 16 (100)
High ALP (N. 120 - 360 U/L) 2122.5 (772 - 4640) 16 (100)
High GGT ( N. 0 - 34 U/L) 251 (121 - 445) 14 (87.5)
High ALT (N. 10 - 55 U/L) 104 (69 - 296) 11 (68.7)
High AST (N. 10 - 40 U/L) 108 (49 - 316) 9 (56.2)
Low serum albumin (˂ 32 g/L) 5 (31.2)
Prolonged prothrombine time (˃ 15 s) 14 (87.5)
Low serum calcium (˂ 2.2 mmol/L) 8 (50)
Low serum phosphate (˂ 1.4 mmol/L 14 ( 87.5)
Liver imaging (nodular) 3 (18.7)
a  Abbreviations: ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; GGT, Gamma glutamyl transferase.
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Figure 2. Alpha Fetoprotein (AFP) During Treatment in 16 Patients
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Figure 3. Values of GGT Gamma Glutamyl Transferase, GPT (ALT) Alanine 
Aminotransferase and GOT (AST) Aspartate Aminotransferase of 16 Pa-
tients at Presentation
5. Discussion
The interest for genetic disorders is relatively recent 
in Libya, where many sick babies or unexplained in-
fant deaths may be attributable to inborn errors of me-
tabolism. The preliminary investigations fail to give a 
diagnostic clue, the patients actually pass away with-
out metabolic workup because lack of awareness and 
limited diagnostic facilities. HTI is a genetic autosomal 
recessive disorder; the risk is greater in mating relation-
ships where the parents are close relatives. Libya displays 
some of the highest consanguinity rates in the world. 
According to 2008 estimate it was as high as 48.4% in a 
total population of 6.18 million (11). Considering that 16 
patients all of whom, were referred to a single hospital, 
with 81.2% consanguinity rate, it seems that HTI is one of 
the most commonly recognized rare disorders in Libya. 
From other countries in North Africa, namely Tunisia, 
more than 70 cases were reported since 1987 with 25 NTBC 
treated patients since 2000 (Dr. E. Barkaoui, Tunisia In-
ternational Multicenter Study 19 cases and Dr. H Azzouz, 
Tunisia experience in management of HTI,  MEMG 2012), 
from Algeria 30 treated patients and Morocco 3 patients 
(Swedish Orphan communication). The mortality is quite 
high in untreated patients. Three treatment options are 
offered to HTI. The first option is dietary treatment that 
results in a poor outcome and caries a high risk of HCC, 
the second option is the liver transplantation which be-
came the efficient treatment with good survey, and the 
third option is the NTBC which has been available since 
1992, has transformed the prognosis and has obviously 
improved the survival rate of HTI in all forms particularly 
in acute liver failure. NTBC has been used since 2001 as 
treatment for HTI in Libya. Of patients exposed to NTBC, 
60% of patients (n = 9) with more than 3 years, 40% (n = 
6) with more than 6 years and 2 patients with more than 
8 years of NTBC exposure. In none of the patients liver 
transplant was carried out. Three patients died, the cause 
of death was either late diagnosis or delayed starting of 
treatment but HCC was not ruled out (12, 13). Liver trans-
plantation is under developing in Libya. Our next step is 
looking for gene mutations.
Liver transaminases are helpful in recognizing the liver 
disease. We found that elevated GGT was a better marker 
(Figure 3) with respect to following: 1) At presentation 
it was high and increased earlier than other enzymes in 
87.5% of patients. 2) Remained longer high in the first 6 
months after starting treatment except in 2 asymptom-
atic screened babies. 3) It was highly associated with high 
ALP in all patients. 4) It was the first enzyme that raised 
alarm when treatment in patients who previously had re-
sponded well was inadequate.
All patients showed remarkable improvement of the 
signs of rickets after one year of treatment. The renal 
tubulopathy associated with HTI treated with NTBC 
is usually reversible (14). No patient presented with 
neurological manifestation but we faced porphyric 
like crisis in one very well responding, early treated 
asymptomatic screened patient after 6 years of NTBC 
treatment there occurred a sudden acute shortage in 
NTBC, his δ-aminolevulinic acid was high, more than 
20 times above the upper limit of normal, the recovery 
was achieved with reintroducing NTBC and supportive 
treatment. The side effects of NTBC, were seen in most 
of our patients leucopenia and thrombocytopenia, 
were transient but we never observed toxic signs of the 
eyes such as keratitis, photophobia and corneal opaci-
ties (15), nor did we observe skin exfoliative dermatitis 
a sign of high blood tyrosine associated with uncon-
trolled diet restriction.
Conclusions of the present study are as follows: 1. The 
study illustrates achievement of good results in Libya. 2. 
NTBC is well tolerated and has low adverse effects with 
good longterm outcome. 3. High risk groups with per-
sisting high AFP, should be followedup for HCC. 4. GGT 
is a cholestatic parameter, and is the most sensitive 
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liver enzymes marker. 5. ALP is constantly high even in 
asymptomatic patients and could be an early marker. 6. 
Fast dropping of AFP in the third month is a marker of 
good prognosis. 7. Introducing of neonatal metabolic 
screening, possibility of liver transplantation, promo-
tion of local metabolic laboratories and a molecular 
testing is needed.
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